Page 10 - Vertex Effects News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Vertex effects. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Vertex Effects Today - Breaking & Trending Today

Conestoga Capital Advisors LLC Has $76.31 Million Stock Position in Vertex, Inc. (NASDAQ:VERX)

Conestoga Capital Advisors LLC increased its holdings in shares of Vertex, Inc. (NASDAQ:VERX – Free Report) by 19.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,832,620 shares of the company’s stock after buying an additional 452,840 shares during the quarter. Conestoga Capital Advisors […] ....

United States , Jeffrey Westphal , Swiss National Bank , Conestoga Capital Advisors , Vertex Inc , Securities Exchange Commission , Fbo Ann , York Mellon Corp , Dimensional Fund Advisors , Goldman Sachs Group , Needham Company , Vertex Company Profile , Us Bancorp , Exchange Commission , Free Report , Capital Advisors , National Bank , New York Mellon Corp , Fund Advisors , Stock Down , Get Free Report , Item Second , Trust Fbo Ann , Visit Holdingschannel , Vertex Daily , Nasdaq Verx ,

Vertex Advances Inaxaplin Into Phase 2/3 Trial To Treat APOL1-Mediated Kidney Disease

Vertex Pharmaceuticals Inc. (VRTX) announced Monday that inaxaplin (VX-147) has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD), where a 45 mg once daily oral dose will be compared to placebo, on top of standard of care. ....

European Medicines Agency , Drug Administration , Data Monitoring Committee , Vertex Pharmaceuticals Inc , Vertex Pharmaceuticals , Independent Data Monitoring Committee , Rare Pediatric Disease Designation , Breakthrough Therapy Designation , Priority Medicines , Orphan Drug , Pol1 Mediated Kidney Disease ,